Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, multi-institutional study. The study ...

Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported. Active surveillance (AS) should be cautiously offered to men ...

An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

Please provide your email address to receive an email when new articles are posted on . Although active surveillance is acceptable for low-risk prostate cancers, the strategy may be risky for patients ...

Robert De Niro, Warren Buffett and Ben Stiller had prostate cancer, detected at an early-enough stage to allow for recovery. Their treatments included surgery and radiation -- which may sometimes ...

March 4, 2010 — The results of a landmark study often represent the definitive word clinically. For the landmark Radiation Therapy Oncology Group (RTOG) 94-08 study, which evaluated short-term hormone ...

It remains unknown whether or not short-term androgen deprivation (STAD) improves survival among men with intermediate-risk prostate cancer (IRPC) treated with dose-escalated radiotherapy (RT).

Researchers have characterized prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour ...

SAN ANTONIO, October 22, 2018 -- Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, ...

Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond ...